SCHEMBL4309188

SCHEMBL4309188

CCCN(CC1CC1)C(=O)Cn1c(=O)c(C(C)(C)C)cc2ccc(OC)cc21

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.39
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CCR9 P51686 1/20 0.38
CRHR1 P34998 2/20 0.37
MMP1 P03956 1/20 0.37
MMP3 P08254 1/20 0.37
MMP7 P09237 1/20 0.37
MMP13 P45452 1/20 0.37
LMNA P02545 1/20 0.36
MLYCD O95822 1/20 0.35
CNR2 P34972 2/20 0.35
CNR1 P21554 1/20 0.35
MTNR1A P48039 2/20 0.35
MTNR1B P49286 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4318320 0.86 MAPT (0.40) MAPTCCR9LMNAMTNR1AMTNR1B
SCHEMBL4307806 0.85 MAPT (0.39) MAPTMEN1ALDH1A1MAPK1KMT2A
SCHEMBL4312933 0.85 MAPT (0.40) MAPTCCR9LMNAMTNR1AMTNR1B
SCHEMBL4309693 0.85 MAPT (0.42) MAPTALDH1A1SMN1; SMN2CCR9LMNA
SCHEMBL4303825 0.85 PTGDR2 (0.38) MAPTMEN1ALDH1A1MAPK1KMT2A
SCHEMBL4323857 0.84 MAPT (0.39) MAPTCCR9LMNAMTNR1AMTNR1B
SCHEMBL4314697 0.84 MTNR1A (0.41) MAPTMEN1ALDH1A1MAPK1KMT2A
SCHEMBL4307754 0.84 LYN (0.41) MAPTMEN1ALDH1A1MAPK1KMT2A
SCHEMBL4311962 0.81 MAPT (0.41) MAPTCCR9MTNR1AMTNR1B
SCHEMBL4314952 0.81 MAPT (0.42) MAPTCCR9MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062280-A1 Ophthalmic Compositions for Treating Ocular Hypertension MERCK SHARP & DOHME CORP. 2009-03-05 US claimed
US-20090062280-A1 Ophthalmic Compositions for Treating Ocular Hypertension MERCK SHARP & DOHME CORP. 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062280-A1 Ophthalmic Compositions for Treating Ocular Hypertension KCNN3, KCNN1, KCNN2 MAPT 498/4885MEN1 984/4885ALDH1A1 1707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.